Preparation method of compound amino acid injection 18AA-II without antioxidant
By controlling the oxygen content and the raw material dissolution method, especially the hydrochloric acid dissolution of cystine and the sodium hydroxide-assisted dissolution, an antioxidant-free compound amino acid injection was prepared, which solved the problem of easy oxidation of cystine and improved the product stability and safety.
Patent Information
- Application Number
- CN202211710875.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-29
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2042-12-29
AI Technical Summary
The existing compound amino acid injection has the problem that cystine is easily oxidized, which leads to product instability. In addition, the added antioxidants are harmful to some people, increasing the risk of clinical application.
By controlling the oxygen content and raw material dissolution method during the production process, especially by dissolving cystine separately in hydrochloric acid to form a third drug solution and slowly adding it to other amino acid solutions in the presence of sodium hydroxide to avoid the instability of cystine in alkaline solutions, combined with nitrogen rinsing and high-temperature treatment, an antioxidant-free compound amino acid injection solution was prepared.
Without the addition of antioxidants, the stability of cystine is improved, ensuring the stability of the product during storage, transportation and use, reducing the safety risks of clinical use, and the product quality is superior to commercially available products containing antioxidants.
Smart Images

Figure BDA0004027387960000071 
Figure BDA0004027387960000081 
Figure BDA0004027387960000091
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of compound amino acid preparations, and in particular to a method for preparing an antioxidant-free compound amino acid injection 18AA-II. Background Art
[0002] Since amino acids (especially cystine) are unstable, they are easily oxidized when in contact with air during the production process, causing the solution to turn yellow. In order to ensure the stability of product quality, most of the compound amino acid preparations containing cystine currently on the market contain antioxidants (mainly sulfites) to solve the problem of unstable amino acids being easily oxidized. However, since sulfites can easily cause allergic reactions in susceptible populations (such as asthmatics) and even induce toxic effects, increasing the risk of clinical application, compound amino acid preparations that do not contain sulfites or have lower sulfite content are recommended for patients with long-term parenteral nutrition, dysfunction of important organs, critical illness, children, the elderly, and a history of high-risk allergies. European and American countries have formally required pharmaceutical manufacturers to indicate the content of added antioxidants and their adverse reactions in the drug instructions. The "Announcement of the General Administration on the Revision of the Instructions for Compound Amino Acid Injection (18AA) and Similar Preparations" issued by the State Food and Drug Administration (CFDA) in September 2016 also made the same requirement. In addition to compound amino acid injection 18AA, compound amino acid injection 18AA-II also requires the use of unstable cystine and faces the clinical risk of antioxidants. How to reduce the amount of antioxidants in compound amino acid injection 18AA-II or even not use antioxidants at all is the current research focus.
[0003] In the prior art, in order to reduce the amount of antioxidants in the recurrent amino acid injection, most of them are to avoid amino acid oxidation by controlling the oxygen content in the production process. For example, the patent with publication number CN109381423A discloses a preparation method of a pharmaceutical composition containing 19 kinds of amino acids, the pharmaceutical composition comprises 19 kinds of amino acids, pH regulator and water, by controlling the content of dissolved oxygen in the injection and headspace oxygen in the injection storage container, so that it can be stably present under the condition of not containing pyrosulfite or sulfite antioxidants, and then thoroughly solves the harm of pyrosulfite or sulfite antioxidants to human body. However, the pharmaceutical composition provided by the patent does not contain cystine in substance, but uses cysteine, which is also a broad antioxidant in itself, and it has a certain antioxidant effect. If very unstable cystine is added to the amino acid injection, and cysteine that can be used as an antioxidant is not added at the same time, it is difficult to avoid cystine oxidation only by controlling the oxygen content.
[0004] In view of this, it is necessary to design an improved method for preparing the compound amino acid injection 18AA-II without antioxidants to solve the above problems. Summary of the invention
[0005] In view of the above-mentioned defects of the prior art, the object of the present invention is to provide a method for preparing a compound amino acid injection 18AA-II containing cystine but not cysteine and other antioxidants, thereby improving the safety of clinical medication while removing antioxidants and ensuring product quality.
[0006] To achieve the above object, the present invention provides a method for preparing a compound amino acid injection 18AA-II without an antioxidant, comprising the following steps:
[0007] S1. Flushing and passivation of the liquid distribution system and pipelines;
[0008] S2, adding a predetermined amount of water for injection into a batching device, filling nitrogen into the batching device until the amount of dissolved oxygen in the liquid reaches a predetermined range, and then adding sodium hydroxide to obtain a first liquid medicine;
[0009] S3, after heating the first liquid medicine to a predetermined temperature, adding isoleucine, leucine, valine, tyrosine, lysine, methionine, threonine, alanine, arginine, aspartic acid, glutamic acid, proline, serine, glycine, phenylalanine, histidine, and tryptophan, and stirring and dissolving them one by one to obtain a second liquid medicine;
[0010] S4, dissolving cystine with a hydrochloric acid solution to obtain a third liquid;
[0011] S5, adding the third liquid medicine to the second liquid medicine, and then using water for injection to make up to the full amount, and stirring at a temperature of 100°C to obtain a fourth liquid medicine;
[0012] S6. After adding a pH adjuster to adjust the pH of the fourth liquid, the fourth liquid is filled and sterilized to obtain the antioxidant-free compound amino acid injection 18AA-II.
[0013] As a further improvement of the present invention, for each preparation of 10000 mL of the compound amino acid injection 18AA, the amount of each raw material is: isoleucine 20-65g, leucine 30-85g, valine 25-80g, tyrosine 1-4g, lysine 50-135g, methionine 20-65g, threonine 20-65g, alanine 65-170g, arginine 40-120g, aspartic acid 10-40g, glutamic acid 20-60g, proline 25-75g , 15-50g of serine, 30-85g of glycine, 30-85g of phenylalanine, 25-75g of histidine, 5-25g of tryptophan, 1-4g of cystine, and 11-13g of sodium hydroxide added in step S2; the sodium hydroxide added in step S2 is added to the batching device in solid form, or is pre-prepared into a sodium hydroxide solution and then added to the batching device, and the concentration of the sodium hydroxide solution is 1% to 20%, preferably 5% to 15%, and more preferably 10%.
[0014] As a further improvement of the present invention, in step S4, the concentration of the hydrochloric acid solution is 0.8-1.2 mol / L, preferably 1 mol / L; for every 10000 mL of the compound amino acid injection 18AA-II, the amount of the hydrochloric acid solution added is 20-100 mL, preferably 70 mL.
[0015] As a further improvement of the present invention, in step S6, the pH adjuster is a sodium hydroxide solution, which is used to adjust the pH value of the fourth liquid medicine to 5.0-6.2; the concentration of the sodium hydroxide solution is 8%-12%, preferably 10%.
[0016] As a further improvement of the present invention, in step S1, the flushing passivation includes the following steps:
[0017] First, the liquid preparation system and pipelines are circulated and flushed with sodium carbonate solution, and after the sodium carbonate solution is completely drained, the liquid preparation system and pipelines are flushed with injection water until the pH value of the flushing water is 5.0-7.0 and the conductivity is less than 1 μs / cm;
[0018] Then, the disodium edetate solution is used to circulate and flush the liquid preparation system and pipelines. After the disodium edetate solution is completely discharged, the liquid preparation system and pipelines are flushed with injection water until the pH value of the flushing water is 5.0-7.0 and the conductivity is less than 1 μs / cm.
[0019] As a further improvement of the present invention, in step S2, the amount of water for injection is 40% to 70% of the total amount, preferably 50%; the predetermined range of the amount of dissolved oxygen in the liquid is ≦500 PPBO 2 .
[0020] As a further improvement of the present invention, in step S3, the first medicinal solution is heated to 40-80°C, preferably 45-55°C; each amino acid added in step S3 is added in the form of its free base or salt, and the salt form includes hydrochloride or acetate.
[0021] As a further improvement of the present invention, in step S5, the insulation temperature is 50±5°C, and the insulation stirring time is 5 to 30 minutes, preferably 10 to 25 minutes.
[0022] As a further improvement of the present invention, in step S6, the residual oxygen content is controlled at 0-3.0%, preferably 0-1.5%, and more preferably 0-1.0% during filling; the sterilization adopts the overkill method, and the sterilization conditions are sterilization at 121°C for 12-30 minutes.
[0023] As a further improvement of the present invention, it also includes the addition of in vitro nutritional supplements; the in vitro nutritional supplements are preferably one or more of xylitol, glucose, calcium gluconate, potassium chloride, sodium chloride, calcium chloride, chromium chloride, cupric sulfate, ferrous sulfate, magnesium sulfate, zinc chloride, cupric chloride, manganese chloride, and sodium selenite.
[0024] The beneficial effects of the present invention are:
[0025] 1. The preparation method of the antioxidant-free compound amino acid injection 18AA-II provided by the present invention comprises the following steps: by controlling the adding method of cystine, firstly dissolving the amino acids other than cystine with sodium hydroxide at a higher temperature to prepare a second liquid; dissolving cystine alone with a hydrochloric acid solution to form a third liquid, so that cystine exhibits higher stability in the hydrochloric acid solution; and then slowly adding the third liquid into the second liquid, thereby effectively avoiding the influence of the instability of cystine in an alkaline solution on the product quality.
[0026] 2. The present invention regulates the oxygen content of the production process, the dissolution method of the raw materials and the order of addition, and specifically limits the composition and dosage of the raw materials according to the product requirements of the compound amino acid injection 18AA-II. Under the condition of using cystine, antioxidants can still be added without adding, avoiding the toxic effects caused by the addition of antioxidants, solving the clinical risks of antioxidant-containing products from the root, and improving the safety of clinical medication. In addition, the compound amino acid injection 18AA-II provided by the present invention can still ensure the stability of the product during storage, transportation, and use without containing antioxidants, and will not cause the product quality to decline due to the instability of amino acids. Instead, it can avoid the problem of cystine being consumed in large quantities by antioxidants due to the presence of antioxidants, making the product quality better than the commercially available compound amino acid injection 18AA-II containing antioxidants. DETAILED DESCRIPTION
[0027] In order to make the purpose, technical solutions and advantages of the present invention more clear, the present invention is described in detail below in conjunction with specific embodiments.
[0028] In addition, it should be noted that the terms "comprises", "includes" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, method, article or apparatus that includes a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or apparatus.
[0029] The present invention provides a method for preparing an antioxidant-free compound amino acid injection 18AA-II, comprising the following steps:
[0030] S1. Flushing and passivation of the liquid distribution system and pipelines;
[0031] S2, adding a predetermined amount of water for injection into a batching device, filling nitrogen into the batching device until the amount of dissolved oxygen in the liquid reaches a predetermined range, and then adding sodium hydroxide to obtain a first liquid medicine;
[0032] S3, after heating the first liquid medicine to a predetermined temperature, adding isoleucine, leucine, valine, tyrosine, lysine, methionine, threonine, alanine, arginine, aspartic acid, glutamic acid, proline, serine, glycine, phenylalanine, histidine, and tryptophan, and stirring and dissolving them one by one to obtain a second liquid medicine;
[0033] S4, dissolving cystine with a hydrochloric acid solution to obtain a third liquid;
[0034] S5, adding the third liquid medicine to the second liquid medicine, and then using water for injection to make up to the full amount, and stirring at a temperature of 100°C to obtain a fourth liquid medicine;
[0035] S6. After adding a pH adjuster to adjust the pH of the fourth liquid, the fourth liquid is filled and sterilized to obtain the antioxidant-free compound amino acid injection 18AA-II.
[0036] Through the above method, the stability of cystine can be effectively improved, and the influence of the instability of cystine in alkaline solution on the product quality can be avoided. Thus, while not containing antioxidants, the stability of the product during storage, transportation and use can still be guaranteed, and the product quality of the compound amino acid injection 18AA-II can be improved.
[0037] Specifically, for each preparation of 10000 mL of the compound amino acid injection 18AA, the dosage of each raw material is: isoleucine 20-65 g, leucine 30-85 g, valine 25-80 g, tyrosine 1-4 g, lysine 50-135 g, methionine 20-65 g, threonine 20-65 g, alanine 65-170 g, arginine 40-120 g, aspartic acid 10-40 g, glutamic acid 20-60 g, proline 25-75 g, serine 15-50 g, glycine 30-85 g, phenylalanine 30-85 g, histidine 25-75 g, tryptophan 5-25 g, and cystine 1-4 g.
[0038] For each preparation of 10000 mL of the compound amino acid injection 18AA-II, the mass of the sodium hydroxide added in step S2 is 11-13 g, and the sodium hydroxide is added to the batching device in solid form, or is pre-prepared into a sodium hydroxide solution and then added to the batching device. The concentration (mass concentration) of the sodium hydroxide solution is 1% to 20%, preferably 5% to 15%, and more preferably 10%.
[0039] In step S1, the flushing passivation comprises the following steps:
[0040] First, the liquid preparation system and pipelines are circulated and flushed with sodium carbonate solution, and after the sodium carbonate solution is completely drained, the liquid preparation system and pipelines are flushed with injection water until the pH value of the flushing water is 5.0-7.0 and the conductivity is less than 1 μs / cm;
[0041] Then, the disodium edetate solution is used to circulate and flush the liquid preparation system and pipelines. After the disodium edetate solution is completely discharged, the liquid preparation system and pipelines are flushed with injection water until the pH value of the flushing water is 5.0-7.0 and the conductivity is less than 1 μs / cm.
[0042] In step S2, the amount of water for injection is 40% to 70% of the total amount, preferably 50%; the predetermined range of the amount of dissolved oxygen in the liquid is ≤ 500 PPBO 2 ; The total amount is the total volume of the compound amino acid injection 18AA-II that needs to be prepared.
[0043] In step S3, the first drug solution is heated to 40-80°C, preferably 45-55°C; each amino acid added in step S3 is added in the form of its free base or salt, and the salt form includes hydrochloride or acetate.
[0044] In step S4, the concentration of the hydrochloric acid solution is 0.8-1.2 mol / L, preferably 1 mol / L; for every 10000 mL of the compound amino acid injection 18AA-II, the amount of the hydrochloric acid solution added is 20-100 mL, preferably 70 mL.
[0045] In step S5, the insulation temperature is 50±5°C, and the insulation stirring time is 5 to 30 minutes, preferably 10 to 25 minutes.
[0046] In step S6, the pH regulator is a sodium hydroxide solution, which is used to adjust the pH value of the fourth liquid medicine to 5.0-6.2; the concentration (mass concentration) of the sodium hydroxide solution is 8%-12%, preferably 10%; during the filling, the residual oxygen content is controlled at 0-3.0%, preferably 0-1.5%, and more preferably 0-1.0%; the sterilization adopts the overkill method, and the sterilization conditions are sterilization at 121°C for 12-30 minutes.
[0047] In some embodiments of the present invention, in vitro nutritional supplements can also be added during the preparation of the compound amino acid injection 18AA-II. The in vitro nutritional supplements can be added together with the amino acids in step S3, or can be added in an additional step; the in vitro nutritional supplements are preferably one or more of xylitol, glucose, calcium gluconate, potassium chloride, sodium chloride, calcium chloride, chromium chloride, copper sulfate, ferrous sulfate, magnesium sulfate, zinc chloride, copper chloride, manganese chloride, and sodium selenite.
[0048] The preparation method of the antioxidant-free compound amino acid injection 18AA-II provided by the present invention is described below in conjunction with specific examples.
[0049] Examples 1 to 3
[0050] Examples 1 to 3 provide a compound amino acid injection 18AA-II without an antioxidant. Taking the preparation of 10000 mL of the compound amino acid injection 18AA-II as an example, the corresponding prescription amounts of each raw material in each example are shown in Table 1.
[0051] Table 1 Prescription amount of each raw material in the antioxidant-free compound amino acid injection 18AA-II provided in Examples 1 to 3
[0052]
[0053]
[0054] Examples 1 to 3 also provide a method for preparing the above-mentioned antioxidant-free compound amino acid injection 18AA-II. The difference between the embodiments mainly lies in the different compositions. The preparation methods all include the following steps:
[0055] S1. Flushing and passivation of the liquid distribution system and pipelines:
[0056] First, the liquid preparation system and pipelines are circulated and flushed with 3% sodium carbonate solution for 20 minutes. After the sodium carbonate solution is completely drained, the liquid preparation system and pipelines are flushed with injection water until the pH value of the rinse water is the same as that of the injection water and the conductivity is less than 1μs / cm.
[0057] Then, the disodium edetate solution of 1‰ (g / ml) was used to circulate and flush the disodium edetate system and pipelines for 20 minutes. After the disodium edetate solution was completely drained, it was flushed with water for injection until the pH value of the rinse water was the same as that of the water for injection and the conductivity was less than 1μs / cm, thus completing the flushing passivation of the disodium edetate system and pipelines.
[0058] S2. Add 5000mL (50% of the total amount) of water for injection into the batching tank, start stirring and open the nitrogen valve, and fill the batching tank with nitrogen while stirring until the dissolved oxygen content of the liquid is ≦500PPBO 2 Then, a prescribed amount of sodium hydroxide is added (the prescribed amount of sodium hydroxide is dissolved in water for injection and diluted to a concentration of 10% before being added) to obtain a first liquid medicine;
[0059] S3, turning on the steam to heat the first liquid medicine to about 50° C., and then adding the prescribed amount of tyrosine, isoleucine, leucine, lysine, methionine, threonine, valine, alanine, arginine, aspartic acid, glutamic acid, proline, serine, glycine, sorbitol, phenylalanine, histidine, taurine, and tryptophan in order, and stirring and dissolving them one by one to obtain a second liquid medicine;
[0060] S4, dissolving the prescribed amount of cystine with 70 mL of 1 mol / L dilute hydrochloric acid solution to obtain a third liquid;
[0061] S5, adding the third liquid medicine to the second liquid medicine, and then using water for injection to make up to the full amount (10000mL), and stirring at 50±5°C for 15min to obtain a fourth liquid medicine;
[0062] S5. Add 10% sodium hydroxide solution as a pH regulator, adjust the pH value of the third liquid to 5.6, continue stirring for 30 minutes, then stop stirring, and pump the liquid into the liquid storage tank for standby use. After the liquid is tested and qualified, fill it in the infusion bottle with nitrogen, and control the residual oxygen content below 1.0% during the filling process; then sterilize it by overkilling method, the sterilization conditions are 121°C, 12 minutes, and after sterilization, the compound amino acid injection 18AA-II without antioxidant is obtained.
[0063] In order to test the stability of the antioxidant-free compound amino acid injection 18AA-II prepared in Examples 1 to 3, a long-term stability experiment was conducted on the compound amino acid injection 18AA-II prepared in each Example. pH, transmittance (%), insoluble particles, related substances, and amino acid content were used as key evaluation indicators. Samples were taken for testing at 0, 3, 6, 9, 12, and 24 months, respectively, to investigate the stability of the prepared products. Examples 1 to 3 were compared with a commercially available product (compound amino acid injection (18AA-II) produced by Guangdong Otsuka Pharmaceutical Co., Ltd., which contains an antioxidant, sodium metabisulfite). The results are shown in Table 2.
[0064] Table 2 Performance comparison of the antioxidant-free compound amino acid injection 18AA-II prepared in Examples 1 to 3 and commercially available products
[0065]
[0066]
[0067]
[0068]
[0069]
[0070] It can be seen from Table 2 that although the compound amino acid injection 18AA-II prepared in Examples 1 to 3 does not contain any antioxidant, after being stored under long-term conditions for 24 months, the key evaluation indicators have no significant difference from those when the initial preparation is completed, indicating that the compound amino acid injection 18AA-II prepared by the present invention can still maintain good product stability without adding antioxidants.
[0071] At the same time, since the antioxidant sodium pyrosulfite present in the commercially available product will also consume cystine, resulting in a decrease in the actual content of cystine, the cystine in the commercially available product is close to the quality control line after being placed for 24 hours (the Chinese Pharmacopoeia 2020 version stipulates that the cystine content range is 80.0% to 120.0%), which affects the patient's extraction of cystine. The antioxidant-free compound amino acid injection 18AA-II prepared in Examples 1 to 3 can effectively avoid the problem of cystine being consumed in large quantities by the antioxidant due to the presence of the antioxidant, and significantly increase the content of cystine in the compound amino acid injection 18AA-II, which has quality attributes that are significantly better than commercially available products.
[0072] Comparative Example 1
[0073] Comparative Example 1 provides an antioxidant-free compound amino acid injection 18AA-II. Compared with Example 1, the only difference is that the method of adding cystine in step S4 is changed. Instead of dissolving cystine alone with a hydrochloric acid solution, cystine is directly added to a second medicinal solution with sodium hydroxide as a co-solvent. The remaining steps and the prescription amounts of the raw materials are the same as those in Example 1 and are not repeated here.
[0074] The transmittance of the compound amino acid injection 18AA-II obtained in this comparative example was tested and compared with that of Example 1 and commercially available products. The results are shown in Table 3.
[0075] Table 3 Performance comparison of Example 1, Comparative Example 1 and commercially available products
[0076]
[0077] It can be seen from Table 3 that in Comparative Example 1, cystine is directly added to the second liquid with sodium hydroxide as a co-solvent in a conventional manner. Since no antioxidant is added, the transmittance of the prepared compound amino acid injection 18AA-II cannot reach the corresponding limit requirement after being placed for 3 months, and the product quality does not meet the standard; and although the commercially available product can meet the corresponding limit requirements because of the addition of antioxidants, the addition of antioxidants also increases the risk of clinical application and will affect the actual content of cystine.
[0078] Compared with Comparative Example 1 and commercially available products, Example 1 adjusts the method of adding cystine, dissolves cystine alone in a hydrochloric acid solution to form a third liquid, and then adds cystine to a second liquid formed by other amino acids with sodium hydroxide as a co-solvent, so that the corresponding limit requirements can still be met after being placed for 24 months without adding any antioxidant. The light transmittance at each time stage is even higher than that of the commercially available product with added antioxidants, showing higher stability. At the same time, the clinical risks caused by the addition of antioxidants and the problem of cystine consumption are avoided, and the product quality is significantly better than the commercially available product containing antioxidants.
[0079] Example 4
[0080] This embodiment provides a method for preparing an antioxidant-free compound amino acid injection 18AA-II. Compared with Example 1, the difference is that the sterilization conditions in step S6 are changed. The sterilization conditions in this embodiment are 121°C and 15 minutes. The remaining steps are consistent with Example 1 and are not repeated here.
[0081] Compared with Example 1, this example significantly improves the sterility assurance level of the product by extending the sterilization time and using an overkilling method. However, most of the compound amino acid products currently on the market use auxiliary sterilization methods, which poses a safety hazard in clinical use.
[0082] In summary, the present invention provides a method for preparing a compound amino acid injection 18AA-II that does not contain an antioxidant. The preparation method includes flushing and passivating the liquid preparation system and pipelines; after nitrogen is filled into the batching device for adding water for injection to adjust the dissolved oxygen content of the liquid, sodium hydroxide is added, and then the liquid is heated and other amino acids except cystine are added one by one to obtain a second liquid; after cystine is dissolved in a hydrochloric acid solution to form a third liquid, the third liquid is added to the second liquid, and after constant volume, pH adjustment, filling, sterilization and other processes, a compound amino acid injection 18AA-II that does not contain an antioxidant is obtained. Through the above-mentioned method, the present invention can make cystine show higher stability, and can still ensure the stability of the product during storage, transportation and use without adding antioxidants, which not only improves the safety of clinical medication, but also improves product quality.
[0083] The above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention may be modified or replaced by equivalents without departing from the spirit and scope of the technical solution of the present invention.
Claims
1. A method for preparing a compound amino acid injection 18AA-II without an antioxidant, It is characterized in that The steps include: S1. Flushing and passivation of the liquid distribution system and pipelines; S2, adding a predetermined amount of water for injection into a batching device, filling nitrogen into the batching device until the amount of dissolved oxygen in the liquid reaches a predetermined range, and then adding sodium hydroxide to obtain a first liquid medicine; S3, heating the first liquid to 45-55° C., then adding isoleucine, leucine, valine, tyrosine, lysine, methionine, threonine, alanine, arginine, aspartic acid, glutamic acid, proline, serine, glycine, phenylalanine, histidine, and tryptophan, and stirring and dissolving them one by one to obtain a second liquid; S4, dissolving cystine with a hydrochloric acid solution to obtain a third liquid; The concentration of the hydrochloric acid solution is 0.8-1.2 mol / L; S5, adding the third liquid medicine to the second liquid medicine, and then using water for injection to make up to the full amount, and stirring at a temperature of 100°C to obtain a fourth liquid medicine; S6, adding a pH adjuster to adjust the pH value of the fourth liquid to 5.0-6.2, and filling and sterilizing to obtain a compound amino acid injection 18AA-II without an antioxidant; For each preparation of 10000 mL of the compound amino acid injection 18AA-II, 11-13 g of sodium hydroxide is added in step S2, and 20-100 mL of the hydrochloric acid solution is added in step S4.
2. The method for preparing the antioxidant-free compound amino acid injection 18AA-II according to claim 1, Features: For each preparation of 10000mL of the compound amino acid injection 18AA-II, the amount of each raw material is as follows: isoleucine 20-65g, leucine 30-85g, valine 25-80g, tyrosine 1-4g, lysine 50-135g, methionine 20-65g, threonine 20-65g, alanine 65-170g, arginine 40-120g, aspartic acid 10-40g, glutamic acid 20-60g, proline 25-75g, serine 15-50g, glycine 30-85g, phenylalanine 30-85g, histidine 25-75g, tryptophan 5-25g, and cystine 1-4g; the sodium hydroxide added in step S2 is added to the batching device in solid form, or is pre-prepared into a sodium hydroxide solution and then added to the batching device, and the concentration of the sodium hydroxide solution is 1%-20%.
3. The method for preparing the antioxidant-free compound amino acid injection 18AA-II according to claim 2, Features: The concentration of the sodium hydroxide solution is 5% to 15%.
4. The method for preparing the antioxidant-free compound amino acid injection 18AA-II according to claim 2, Features: The concentration of the sodium hydroxide solution is 10%.
5. The method for preparing the antioxidant-free compound amino acid injection 18AA-II according to claim 1, Features: The concentration of the hydrochloric acid solution is 1 mol / L; for every 10000 mL of the compound amino acid injection 18AA-II, the amount of the hydrochloric acid solution added is 70 mL.
6. The method for preparing the antioxidant-free compound amino acid injection 18AA-II according to claim 1, Features: In step S6, the pH adjuster is a sodium hydroxide solution; the concentration of the sodium hydroxide solution is 8% to 12%.
7. The method for preparing the antioxidant-free compound amino acid injection 18AA-II according to claim 6, Features: The concentration of the sodium hydroxide solution is 10%.
8. The method for preparing the antioxidant-free compound amino acid injection 18AA-II according to claim 1, Features: In step S1, the flushing passivation comprises the following steps: First, the liquid preparation system and pipelines are circulated and flushed with sodium carbonate solution, and after the sodium carbonate solution is completely drained, the liquid preparation system and pipelines are flushed with injection water until the pH value of the flushing water is 5.0-7.0 and the conductivity is less than 1 μs / cm; Then, the disodium edetate solution is used to circulate and flush the liquid preparation system and pipelines. After the disodium edetate solution is completely discharged, the liquid preparation system and pipelines are flushed with injection water until the pH value of the flushing water is 5.0-7.0 and the conductivity is less than 1 μs / cm.
9. The method for preparing the antioxidant-free compound amino acid injection 18AA-II according to claim 1, Features: In step S2, the amount of water for injection is 40% to 60% of the total amount; the predetermined range of the dissolved oxygen content is ≤ 500 PPBO 2 .
10. The method for preparing the antioxidant-free compound amino acid injection 18AA-II according to claim 9, Features: The amount of the water for injection is 50% of the total amount.
11. The method for preparing the antioxidant-free compound amino acid injection 18AA-II according to claim 1, Features: Each amino acid added in step S3 is added in the form of its free base or salt, and the salt form includes hydrochloride or acetate.
12. The method for preparing the antioxidant-free compound amino acid injection 18AA-II according to claim 1, Features: In step S5, the insulation temperature is 50±5° C., and the insulation stirring time is 5 to 30 minutes.
13. The method for preparing the antioxidant-free compound amino acid injection 18AA-II according to claim 12, Features: The time of heat preservation and stirring is 10 to 25 minutes.
14. The method for preparing the antioxidant-free compound amino acid injection 18AA-II according to claim 1, Features: In step S6, the residual oxygen content is controlled at 0-3.0% during the filling; the sterilization adopts the overkill method, and the sterilization condition is sterilization at 121° C. for 12-30 minutes.
15. The method for preparing the antioxidant-free compound amino acid injection 18AA-II according to claim 14, Features: During the filling, the residual oxygen content is controlled at 0-1.5%.
16. The method for preparing the antioxidant-free compound amino acid injection 18AA-II according to claim 14, Features: During the filling, the residual oxygen content is controlled at 0-1.0%.
17. The method for preparing the antioxidant-free compound amino acid injection 18AA-II according to claim 1, Features: It also includes the addition of in vitro nutritional supplements.
18. The method for preparing the antioxidant-free compound amino acid injection 18AA-II according to claim 17, Features: The in vitro nutritional supplement is one or more of xylitol, glucose, calcium gluconate, potassium chloride, sodium chloride, calcium chloride, chromium chloride, cupric sulfate, ferrous sulfate, magnesium sulfate, zinc chloride, cupric chloride, manganese chloride, and sodium selenite.
